Gilder Gagnon Howe & Co. LLC Sells 377,423 Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH)

Gilder Gagnon Howe & Co. LLC trimmed its holdings in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 99.4% during the fourth quarter, HoldingsChannel reports. The fund owned 2,356 shares of the medical equipment provider’s stock after selling 377,423 shares during the quarter. Gilder Gagnon Howe & Co. LLC’s holdings in Lantheus were worth $211,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Hancock Whitney Corp raised its position in Lantheus by 2.6% during the 4th quarter. Hancock Whitney Corp now owns 18,366 shares of the medical equipment provider’s stock worth $1,643,000 after purchasing an additional 471 shares during the last quarter. Penn Capital Management Company LLC acquired a new position in shares of Lantheus in the fourth quarter worth approximately $11,790,000. RiverPark Advisors LLC boosted its holdings in Lantheus by 493.3% in the fourth quarter. RiverPark Advisors LLC now owns 3,975 shares of the medical equipment provider’s stock valued at $356,000 after acquiring an additional 3,305 shares during the last quarter. Sirios Capital Management L P boosted its holdings in Lantheus by 22.8% in the fourth quarter. Sirios Capital Management L P now owns 23,183 shares of the medical equipment provider’s stock valued at $2,074,000 after acquiring an additional 4,310 shares during the last quarter. Finally, GMT Capital Corp raised its holdings in Lantheus by 11.7% during the 4th quarter. GMT Capital Corp now owns 457,500 shares of the medical equipment provider’s stock worth $40,928,000 after purchasing an additional 47,800 shares during the last quarter. 99.06% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on LNTH. Truist Financial upped their price objective on shares of Lantheus from $120.00 to $127.00 and gave the company a “buy” rating in a research note on Thursday, February 27th. B. Riley decreased their price target on Lantheus from $127.00 to $122.00 and set a “buy” rating for the company in a report on Friday, March 21st. Finally, JMP Securities reissued a “market outperform” rating and issued a $112.00 price objective on shares of Lantheus in a research note on Tuesday, January 14th. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $129.43.

Lantheus Price Performance

Shares of LNTH opened at $101.77 on Monday. The stock has a 50-day moving average of $97.37 and a 200-day moving average of $95.14. Lantheus Holdings, Inc. has a one year low of $65.76 and a one year high of $126.89. The company has a market cap of $6.97 billion, a PE ratio of 16.93 and a beta of 0.20.

Lantheus (NASDAQ:LNTH) last released its quarterly earnings data on Thursday, February 27th. The medical equipment provider reported $1.34 EPS for the quarter, missing the consensus estimate of $1.57 by ($0.23). Lantheus had a net margin of 28.57% and a return on equity of 44.29%. The firm had revenue of $391.11 million for the quarter, compared to the consensus estimate of $376.61 million. Analysts expect that Lantheus Holdings, Inc. will post 6.01 EPS for the current fiscal year.

Insider Buying and Selling at Lantheus

In related news, CFO Robert J. Jr. Marshall sold 10,000 shares of Lantheus stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $100.52, for a total transaction of $1,005,200.00. Following the transaction, the chief financial officer now owns 113,860 shares of the company’s stock, valued at $11,445,207.20. The trade was a 8.07 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Mary Anne Heino sold 53,107 shares of the stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $94.35, for a total value of $5,010,645.45. Following the completion of the sale, the director now directly owns 440,399 shares of the company’s stock, valued at $41,551,645.65. The trade was a 10.76 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 63,109 shares of company stock valued at $6,016,046. Corporate insiders own 1.50% of the company’s stock.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.